Clinical trial NCT00124189: Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)
Official title: A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of GRN163L in Patients With Chronic Lymphoproliferative Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Chronic Lymphoproliferative Diseases
Keywords: Chronic lymphocytic leukemia
T-cell prolymphocytic leukemia
Chronic lymphoproliferative diseases
Telomerase
Telomerase Inhibition
Lead sponsor: Geron Corporation
Sponsor class: INDUSTRY
First posted: 2005-07-27
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and maximum tolerated dose of GRN163L in treating patients with refractory or relapsed chronic lymphoproliferative disease.

Detailed description: Imetelstat Sodium (GRN163L) is a telomerase template antagonist with in vitro and in vivo activity in a variety of tumor model systems. Telomerase is an enzyme that is active primarily in tumor cells and is crucial for the indefinite growth of tumor cells. Inhibition of telomerase may result in antineoplastic effects. High telomerase levels and short telomere lengths correlate with other markers of poor prognosis in patients with chronic lymphoproliferative disease.

Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* Male or female
* Chronic lymphoproliferative disease with related biology or similar clinical pattern to B-Cell Leukemia (CLL)including: small lymphocytic lymphoma (SLL), T cell prolymophocytic leukemia (T-PLL), B cell prolymphocytic leukemia (B-PLL), mantle cell lymphoma or other non-Hodgkins lymphoma in leukemic phase (peripheral blood circulating malignant cells present), Waldenstrom's macroglobulinemia
* Must have relapsed from or be refractory to prior therapeutic regimens
* Patients with CLL or SLL must have received at least one prior purine analogue-based chemotherapy regimen (eg, fludarabine, pentostatin or cladribine)
* If previously treated with an anthracycline, anthracenedione, or trastuzumab, must have left ventricular ejection fraction \> 50%
* ECOG performance status 0-2
* Life expectancy 3 months or greater

Exclusion Criteria:

* Pregnant or lactating women
* Active 2nd malignancy or history of another malignancy within 2 years, except:treated, non-melanoma skin cancer,treated breast or cervical carcinoma in situ,or resected T1a or b prostate cancer
* Chemotherapeutic agents within 4 weeks prior to study
* High dose CTX with stem cell support within 6 months prior to study
* Signal transduction inhibitors,or monoclonal antibodies within 4 weeks prior to study
* Immunotherapy or biological response modifiers within 4 weeks prior to study
* Systemic hormonal therapy within 4 weeks prior to study
* Anticoagulant therapy, antiplatelet therapy within 2 weeks prior to study
* Radiotherapy within 4 weeks prior to study
* Active autoimmune disorder
* Central nervous system or leptomeningeal involvement
* Clinically significant cardiovascular disease
* Known HIV infection
* Serious/active infection
* Surgical procedure within 2 weeks

Primary outcomes:
measure: Safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or recommended phase II dose of GRN163L in patients with relapsed or refractory chronic lymphoproliferative disease
timeFrame: First 3 weeks
Secondary outcomes:
measure: PK and PD
timeFrame: Measured in the first 6 weeks
Other outcomes:
Locations:
city: Denver
country: United States
facility: Rocky Mountain Cancer Center
state: Colorado
city: Hackensack
country: United States
facility: Hackensack University Medical Center
state: New Jersey
city: Buffalo
country: United States
facility: Roswell Park Cancer Center
state: New York
city: New Hyde Park
country: United States
facility: Long Island Jewish Medical Center
state: New York
city: New York
country: United States
facility: Weill Medical College of Cornell University
state: New York
city: Columbus
country: United States
facility: The Ohio State University James Cancer Hospital
state: Ohio
city: Dallas
country: United States
facility: UT Southwestern
state: Texas
city: San Antonio
country: United States
facility: University of Texas Health Science Center
state: Texas
Study officials:
affiliation: Geron Corporation
name: Stephen Kelsey, MD
role: STUDY_DIRECTOR
References: